CAU
TXG icon

Caxton Associates (UK)’s 10x Genomics TXG Stock Holding History

Caxton Associates (UK)’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$232K Sell
6,044
-8,508
-58% -$223K ﹤0.01% 682
2026
Q1 		$309K Buy
14,552
+2,508
+21% +$50.1K 0.01% 601
2025
Q4 		$196K Sell
12,044
-6,293
-34% -$95.1K ﹤0.01% 717
2025
Q3 		$214K Sell
18,337
-69,069
-79% -$901K 0.01% 621
2025
Q2 		$1.01M Sell
87,406
-259,388
-75% -$2.36M 0.03% 321
2025
Q1 		$3.03M Buy
+346,794
New +$4.37M 0.11% 85

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Caxton Associates (UK)'s TXG Position: Q2 2026 in Review

Caxton Associates (UK) reduced its 10x Genomics (TXG) stake by 58% in Q2 2026, selling an estimated $223K and leaving 6,044 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #682.

Caxton Associates (UK) first reported a position in TXG in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.03M in Q1 2025. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Caxton Associates (UK) held 6,044 shares of 10x Genomics worth $232K as of Q2 2026.
  • Caxton Associates (UK) sold 8,508 10x Genomics shares in Q2 2026, an estimated $223K.
  • 10x Genomics made up ﹤0.01% of Caxton Associates (UK)'s portfolio in Q2 2026, its #682 holding.
  • Caxton Associates (UK) first reported a position in 10x Genomics in Q1 2025 and has held it in 6 quarters since.
  • Caxton Associates (UK)'s 10x Genomics position peaked at $3.03M in Q1 2025.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.